Clesrovimab clinical trials
Also written MK-1654.
How each study uses clesrovimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the clesrovimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 Jun 2025 · ENFLONSIA · BLA 761432 (FDA, Drugs@FDA)
- European Union
- 15 Apr 2026 · Enflonsia · EMEA/H/C/006497 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Studies
Open first, then newest update. How each study uses clesrovimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration EvaluationNot yet recruitingPhase 4Emory UniversityNCT07824167Written as Clesrovimab
- Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)CompletedPhase 3Merck Sharp & Dohme LLCNCT04938830Written as Clesrovimab
- Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT04767373Written as Clesrovimab
- Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT03524118Written as Clesrovimab
- Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)CompletedPhase 2Merck Sharp & Dohme LLCNCT04086472Written as Clesrovimab
Codes
What other systems call clesrovimab · ClinicalTrials.gg INT018253
- UNII (FDA) VJO29R4CP9CLESROVIMABOne source FDA
- NCI Thesaurus C186415ClesrovimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VJO29R4CP9 | CLESROVIMAB | One source FDA |
| NCI Thesaurus | C186415 | Clesrovimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.